March 27th 2024
For most patients younger than age 60 with polycythemia vera (PV) who are not considered high risk, cytoreductive therapies are withheld despite being highly effective.
Success in Eosinophil-Targeted Treatments for EoE Remains Limited
September 2nd 2022The researchers compiled data from studies of lirentelimab, mepolizumab, reslizumab, and benralizumab, highlighting the difficulties in finding an effective approach with eosinophil-targeted treatments for eosinophilic esophagitis (EoE).
Read More
Patients and Parents Impacted by SMA May Be Optimistic About Prenatal Testing, Therapies
September 2nd 2022As the feasibility of phase 1 clinical trials for prenatal spinal muscular atrophy (SMA) therapies is explored, patient and parent input on prenatal testing and possibly treatment is a valuable tool for guiding research discussions.
Read More
What We're Reading: Drug Pricing Debate; Judge Rules Against Walgreens; Predicting TBI Outcomes
August 11th 2022Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.
Read More
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
Read More
Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment
July 28th 2022Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
Read More
Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma
July 16th 2022Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.
Read More
Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%
June 4th 2022Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Read More
Emory’s Haumschild on Need for Clinical Pathways in SCLC: “Not Everyone’s an Expert”
May 18th 2022Ryan Haumschild PharmD, MS, MBA, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute, spoke with AJMC® about health care resource utilization and clinical decision support in the care of patients with small cell lung cancer (SCLC).
Read More
Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.
Read More
Preclinical Data at AACR Show CSP May Be Broad Target in Cholangiocarcinoma
April 13th 2022Researchers presented results for ZB131, a monoclonal antibody that would target cancer-specific plectin (CSP); experiments with mice showed this may be present in more than 80% of the most common types of cholangiocarcinoma.
Read More
Dr Jorge Plutzky Explains How Traditional CV Risk Prediction Models Fall Short for Patients With HIV
March 30th 2022Traditional cardiovascular (CV) risk prediction models may not apply accurately to patients with HIV who may develop the cardiovascular disease younger than usual, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School.
Watch
Dr Shoaib Ugradar Discusses Teprotumumab for Thyroid Eye Disease and Data Collected
March 21st 2022Teprotumumab has shown great efficacy in treating thyroid eye disease in both clinical trials and real-world settings, but more data are needed on adverse events, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Watch
Dr Robert Fante: More Data Will Provide More Insight Into Use of Teprotumumab for TED
March 7th 2022As more data are gathered on teprotumumab for use in thyroid eye disease (TED), we’ll have a better understanding of which subgroups respond better or worse to the treatment, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.
Watch
With Natural Killer Cell Immunotherapy, Alloreactive Cell Dose May Be Predictive of Response
February 26th 2022Research has shown that adoptive immunotherapy using natural killer cells may be beneficial in leukemia treatment. The follow-up to a recent study found that the dose of alloreactive natural killer cells matters for treatment response.
Read More